beijing
Recently, the Chinese Association of Pancreatology (CAP), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) signed a joint strategic cooperation agreement. The delegations that attended the event were led by Yupei Zhao, President of CAP, and Hongbin Dai, President of Hengrui Pharma.
The signing ceremony began on introductory videos presenting the development of both organizations, followed by Chai Jianjun, Secretary-General of CAP, and Huo Shiwen, Vice President of Hengrui Pharma, formally signing the agreement on behalf of their respective parties. The agreement makes Hengrui Pharma the first pharmaceutical company to establish a strategic partnership with CAP.
President Dai Hongbin delivering a speech
President Dai Hongbin stated that Hengrui Pharma, as a leading domestic innovator in pharmaceuticals, has consistently prioritized clinical needs and focused on disease characteristics prevalent in the Chinese population, while continuously increasing investments in innovative drug R&D. To date, the company has developed and launched 18 new molecular entities (Category I new drugs) and four other innovative drugs (Category 2 new drugs) in China, spanning multiple disease areas including pancreatic cancer. Additionally, more than 90 independent innovative products are under clinical development, and about 400 clinical trials are being carried out at home and abroad. Looking forward, both parties will work to strengthen cooperation in clinical research, talent development, international exchanges, and public science education. They will also accelerate the clinical transformation of innovative drugs, in an effort to achieve breakthrough advancements as quickly as possible so as to benefit pancreatic disease patients in China and worldwide.
Academician Zhao Yupei delivering a concluding remark
In Academician Zhao Yupei's concluding remarks, he emphasized that innovation and internationalization are shared goals of both CAP and Hengrui Pharma. This collaboration reflects a mutual commitment to scientific progress and national responsibility. He expressed hope that this agreement will serve as a starting point to address pancreatic diseases — a critical clinical challenge and global medical issue — by implementing a number of directives from the National Health Commission, including improving grassroots access to high-quality medical resources, enhancing bilateral exchanges, generating more scientific achievements, launching the "Pancreatic Health China Initiative" public welfare project, establishing Chinese standards for pancreatic disease prevention and treatment, and contributing "Eastern Wisdom" to international guidelines. By working together, the two sides can strive to overcome the greatest challenges in pancreatic disease prevention and treatment, a goal akin to that of mountaineers who successfully scale Mount Everest.
Under the agreement, both parties will thoroughly implement the national strategy for scientific self-reliance, while focusing on key technological challenges in pancreatic diseases, and jointly establishing major research projects that aim to achieve "zero-to-one" breakthroughs. Together, they will build a three-in-one platform for the "publication, exchange, and evaluation" of research outcomes in order to promote "one-to-ten" scaling of innovations. The parties will also implement the National Health Commission's guidelines on optimizing the layout of grassroots medical institutions, jointly establish projects for grassroots cooperation, and work to widely promote CAP's novel concepts, methods, technologies, and products to grassroots medical institutions nationwide, creating a system for implementation to go from "10 to 100".
Secretary-General Chai Jianjun and Vice President Huo Shiwen at the signing ceremony
Additionally, CAP and Hengrui Pharma will jointly promote international cooperation, support Asia-Pacific and global pancreatic disease summits, and organize branded academic conferences to enhance hospital management and oncology care capabilities. Both parties will collaborate on public education programs that raise awareness of pancreatic diseases and foster societal engagement in prevention and treatment efforts.
A group photo commemorating the strategic partnership agreement
Copyright ©1997- by CRI Online All rights reserved
